Ultragenyx Pharmaceutical Inc
NASDAQ:RARE
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Ultragenyx Pharmaceutical Inc
NASDAQ:RARE
|
US |
|
E
|
Expeditors International of Washington Inc
SWB:EW1
|
US |
|
Organizacion Soriana SAB de CV
F:OSOB
|
MX |
|
S
|
Shimano Inc
XBER:SHM
|
JP |
|
Barclays PLC
LSE:BARC
|
UK |
|
H
|
Hyundai Motor Co
SWB:HYU
|
KR |
|
C
|
CH Robinson Worldwide Inc
LSE:0HQW
|
US |
|
F
|
Ferrari NV
SWB:2FE
|
IT |
|
T
|
Texas Instruments Inc
LSE:0R2H
|
US |
|
F
|
FedEx Corp
XBER:FDX
|
US |
|
Sino Land Co Ltd
HKEX:83
|
HK |
|
Liberty Media Corp
OTC:FWONB
|
US |
Wall St Price Targets
RARE Price Targets Summary
Ultragenyx Pharmaceutical Inc
According to Wall Street analysts, the average 1-year price target for RARE is 53.1 USD with a low forecast of 27.27 USD and a high forecast of 100.8 USD.
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
What is RARE's stock price target?
Price Target
53.1
USD
According to Wall Street analysts, the average 1-year price target for RARE is 53.1 USD with a low forecast of 27.27 USD and a high forecast of 100.8 USD.
What is the Revenue forecast for Ultragenyx Pharmaceutical Inc?
Projected CAGR
23%
The compound annual growth rate for Revenue over the next 8 years is 23%.
What is the Gross Profit forecast for Ultragenyx Pharmaceutical Inc?
Projected CAGR
23%
The compound annual growth rate for Gross Profit over the next 7 years is 23%.
